Protagenic Therapeutics (OTCMKTS:PTIX) Lifted to “Buy” at ValuEngine
PTIX remained flat at $$1.50 on Tuesday. The firm’s 50 day simple moving average is $1.50. Protagenic Therapeutics has a one year low of $1.25 and a one year high of $2.50.
Protagenic Therapeutics (OTCMKTS:PTIX) last announced its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.06) earnings per share for the quarter.
Protagenic Therapeutics, Inc, a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder.
Featured Article: What is a death cross?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.